Pynegabine

Pynegabine
Clinical data
Other namesHN-37
Routes of
administration
Oral
Drug classKv7.2 and Kv7.3 potassium channel opener
Identifiers
  • methyl N-[4-[(4-fluorophenyl)methyl-prop-2-ynylamino]-2,6-dimethylphenyl]carbamate
CAS Number
PubChem CID
ChemSpider
ChEMBL
PDB ligand
Chemical and physical data
FormulaC20H21FN2O2
Molar mass340.398 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC(=C1NC(=O)OC)C)N(CC#C)CC2=CC=C(C=C2)F
  • InChI=1S/C20H21FN2O2/c1-5-10-23(13-16-6-8-17(21)9-7-16)18-11-14(2)19(15(3)12-18)22-20(24)25-4/h1,6-9,11-12H,10,13H2,2-4H3,(H,22,24)
  • Key:HXUBJZRAVCPBRH-UHFFFAOYSA-N

Pynegabine (developmental code name HN37) is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of epilepsy in China. The drug is an analogue of flupirtine and retigabine (ezogabine). However, it shows 55-fold greater potency in activating Kv7.2 channels and 127-fold greater potency in activating Kv7.3 channels compared to retigabine in vitro. In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison. The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao. As of 2026, it is in phase 2 clinical trials for epilepsy.

See also